Vir Biotechnology, Inc. VIR Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s other accrued liabilities?
- Vir Biotechnology, Inc. (VIR) reported other accrued liabilities of $7.11M in Q1 2026.
- How has Vir Biotechnology, Inc.'s other accrued liabilities changed year-over-year?
- Vir Biotechnology, Inc.'s other accrued liabilities increased by 106.1% year-over-year, from $3.45M to $7.11M.
- What is the long-term trend for Vir Biotechnology, Inc.'s other accrued liabilities?
- Over 3 years (2022 to 2025), Vir Biotechnology, Inc.'s other accrued liabilities has grown at a -26.5% compound annual growth rate (CAGR), from $12.71M to $5.04M.